...
首页> 外文期刊>Archives of Internal Medicine >Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
【24h】

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

机译:影响个人的抗逆转录病毒药物心肌梗死的风险免疫缺陷病毒感染患者:一个病例对照研究嵌套在法国医院艾滋病毒艾滋病群体CO4数据库。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The role of exposure to specific antiretroviral drugs on risk of myocardial infarction in human immunodeficiency virus (HIV)-infected patients is debated in the literature. METHODS: To assess whether we confirmed the association between exposure to abacavir and risk of myocardial infarction (MI) and to estimate the impact of exposure to other nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and non-NRTIs on risk of MI, we conducted a case-control study nested within the French Hospital Database on HIV. Cases (n = 289) were patients who, between January 2000 and December 2006, had a prospectively recorded first definite or probable MI. Up to 5 controls (n = 884), matched for age, sex, and clinical center, were selected at random with replacement among patients with no history of MI already enrolled in the database when MI was diagnosed in the corresponding case. Conditional logistic regression models were used to adjust for potential confounders. RESULTS: Short-term/recent exposure to abacavir was associated with an increased risk of MI in the overall sample (odds ratios [ORs], 2.01; 95% confidence interval [CI], 1.11-3.64) but not in the subset of matched cases and controls (81%) who did not use cocaine or intravenous drugs (1.27; 0.64-2.49). Cumulative exposure to all PIs except saquinavir was associated with an increased risk of MI significant for amprenavir/fosamprenavir with or without ritonavir (OR, 1.53; 95% CI, 1.21-1.94 per year) and lopinavir with ritonavir (1.33; 1.09-1.61 per year). Exposure to all non-NRTIs was not associated with risk of MI. CONCLUSION: The risk of MI was increased by cumulative exposure to all the studied PIs except saquinavir and particularly to amprenavir/fosamprenavir with or without ritonavir and lopinavir with ritonavir, whereas the association with abacavir cannot be considered causal.
机译:背景:暴露于特定的角色抗逆转录病毒药物对心肌的风险人类免疫缺陷病毒的梗塞(HIV)来华的病人中讨论文学。证实了协会之间的接触abacavir和心肌梗死(MI)的风险并评估暴露于其他的影响核苷逆转录酶抑制剂(NRTIs)、蛋白酶抑制剂(pi)和non-NRTIs在MI的风险,我们进行了病例对照研究嵌套在法国医院数据库艾滋病毒。2000年1月至2006年12月,有一个前瞻性记录第一次明确的或可能的MI。5控制(n = 884),与年龄、性,和临床中心,是随机选择的替换患者没有历史当MI MI已经进入数据库被诊断出在相应的情况。有条件的使用逻辑回归模型为潜在的混杂因素调整。短期/最近接触abacavir与MI的风险增加有关总体样本(优势比(ORs), 2.01;可信区间(CI), 1.11 - -3.64)但不是的子集匹配情况下和控制(81%)谁不使用可卡因或静脉注射药物(1.27;除了saquinavir与一个MI的风险显著增加amprenavir / fosamprenavir有或没有例如(OR, 1.53;和lopinavir例如(1.33;年)。与MI的风险相关。结论:风险MI增加了累积接触π除了saquinavir和研究尤其是amprenavir / fosamprenavir或没有例如和lopinavir例如而与abacavir不能认为因果。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号